Artikel Bebas

Facebook Like

Article in English
Hepatitis B (Fact Sheet WHO) Print E-mail

WHO Fact sheet, Reviewed July 2017.

Key facts

  • Hepatitis B is a viral infection that attacks the liver and can cause both acute and chronic disease.
  • The virus is transmitted through contact with the blood or other body fluids of an infected person.
  • An estimated 257 million people are living with hepatitis B virus infection (defined as hepatitis B surface antigen positive).
  • In 2015, hepatitis B resulted in 887 000 deaths, mostly from complications (including cirrhosis and hepatocellular carcinoma).
  • Hepatitis B is an important occupational hazard for health workers.
  • However, it can be prevented by currently available safe and effective vaccine.
FibroScan (Vibration-Controlled Transient Elastography): Where Does It Stand in the United States Practice (Elliot B. Tapper, Laurent Castera, and Nezam H. Afdhal) Print E-mail

Sumber : Clinical Gastroenterology and Hepatology 2015;13:27–36

Di tulis oleh : Elliot B. Tapper,* Laurent Castera,# and Nezam H. Afdhal*

*Division of Gastroenterology, Beth Israel Deaconess Medical Center, Harvard Medical School, Boston, Massachusetts; and #Department of Hepatology, Beaujon Hospital, Assistance Publique-Hôpitaux de Paris, INSERM U773, University of Paris-VII, Clichy, France

With widespread screening and increasingly effective treatments for patients with viral hepatitis as well as the increasing prevalence of nonalcoholic fatty liver disease, the population presenting to the care of gastroenterologists and hepatologists is certain to increase. Assessment of advanced liver disease is traditionally invasive and expensive. Vibration-controlled transient elastography, commonly delivered by the FibroScan device, is an option recently approved by the Food and Drug Administration for the noninvasive assessment of liver disease at the point of care. Herein, we review the promise and pitfalls of vibrationcontrolled transient elastography with the aim of providing clinicians with a framework to interpret its results and apply this technology to the changing needs of our patients.

Hepatitis B virus-related decompensated liver cirrhosis: Benefits of antiviral therapy (Cheng et all) Print E-mail

Source : Journal of Hepatology 2012 vol. 57 j 442–450. EASL (European Association for The Study of The Liver) Agustus 2012

Cheng-Yuan Peng1,2, Rong-Nan Chien3, Yun-Fan Liaw4,*

1School of Medicine, China Medical University, Taichung, Taiwan; 2Division of Hepatogastroenterology, Department of Internal Medicine, China Medical University Hospital, Taichung, Taiwan; 3Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Keelung, Taiwan; 4Liver Research Unit, Chang Gung Memorial Hospital, Chang Gung University College of Medicine, Taipei, Taiwan

Received 22 December 2011; received in revised form 9 February 2012; accepted 13 February 2012
⇑ Corresponding author. Address: Liver Research Unit, Chang Gung University and Memorial Hospital, 199, Tung Hwa North Road, Taipei 105, Taiwan. Tel.: +8863 3281200x8120; fax: +886 3 3282824.

More Articles...
« StartPrev12345678NextEnd »

Page 1 of 8

Berbagi Bersama Kami



Visitor Counter

mod_vvisit_counterHari ini100
mod_vvisit_counterMinggu Ini2149
mod_vvisit_counterBulan Ini10683